Managing Life with FTD: Treatment, Strategies, and Caregiver Support
At a Glance
While there is no cure for frontotemporal dementia (FTD), symptoms can be managed to improve quality of life. Care involves securing legal protections, using off-label medications like SSRIs for behavioral issues, adapting the environment, and prioritizing essential caregiver support.
While receiving an FTD diagnosis is overwhelming, it is important to know that while there is currently no cure, there is a standard of care focused on improving the quality of life for both the person with FTD and their caregivers [1][2]. Management is not about “fixing” the brain, but about supporting the person and managing the symptoms through a combination of medication, environmental changes, and specialized support [3][4].
Immediate Safety and Legal Protections
The loss of judgment and executive function in FTD can create immediate, unseen risks:
- Legal and Financial Protections: Because patients can fall for scams or make impulsive financial decisions, it is critical to consult an elder care or disability attorney immediately to secure Financial and Medical Power of Attorney.
- Driving Safety: Impulsivity and loss of judgment make driving incredibly dangerous. Have your neurologist formally evaluate your loved one’s driving safety immediately; leaning on a doctor’s orders can help ease the friction of taking the keys away.
Managing Symptoms with Medication
There are currently no FDA-approved disease-modifying therapies that can stop FTD in its tracks [1]. Instead, doctors use “off-label” medications to manage specific behavioral and psychiatric symptoms:
- Serotonergic Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) are the most common first-line treatment. Research shows they can help reduce symptoms like disinhibition, irritability, impulsivity, and repetitive behaviors [5][6].
- Antipsychotics: These are used only as a last resort. While “atypical” antipsychotics can sometimes help with severe aggression, they carry a FDA Black Box Warning for an increased risk of death in elderly patients with dementia-related psychosis, alongside risks for falls and movement disorders [7][8]. These should be used with extreme caution and full informed consent.
- A Note on Alzheimer’s Meds: Medications like donepezil (Aricept), which are standard for Alzheimer’s, are generally not recommended for FTD and may actually make behavioral symptoms worse [9][10].
Non-Drug Strategies
Non-pharmacological interventions are often the most effective tools for daily life. They focus on adapting the environment to the person’s current abilities [3].
- Coping with Apathy: For profound apathy and loss of empathy, caregivers must recognize that the patient is biologically incapable of generating emotional responses. Do not take their indifference personally. Instead of asking open-ended questions, provide simple, structured choices, and rely on established routines rather than waiting for them to initiate activities.
- Tailored Activity Program (TAP): This is an evidence-based program led by occupational therapists. It identifies the person’s remaining strengths and creates manageable activities that keep them engaged, which has been shown to reduce behavioral outbursts and lower caregiver stress [11][12].
- Communication Support: For those with Primary Progressive Aphasia (PPA), working with a speech-language pathologist can provide tools like communication boards or smartphone apps to help bridge the gap as speech declines [13].
The Caregiver: The Core of the Team
Research consistently shows that FTD caregivers face higher levels of distress and burden than those caring for people with other forms of dementia [4][14]. This is often due to the younger age of the patient and the “active” nature of the behavioral symptoms [15]. To mitigate this burden, build a multidisciplinary team (neurologist, social worker, occupational therapist) and prioritize regular respite care. Seeking breaks is not a luxury; it is a clinical necessity for your long-term health [16].
Common questions in this guide
Are Alzheimer's medications effective for FTD?
How are behavioral symptoms of FTD treated?
What is the best way to handle apathy in someone with FTD?
What immediate legal steps should be taken after an FTD diagnosis?
When should someone with FTD stop driving?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are there any precision medicine clinical trials currently recruiting for my loved one's specific genetic mutation (e.g., C9orf72 or GRN)?
- 2.Should we consider a trial of a selective serotonin reuptake inhibitor (SSRI) to manage symptoms of disinhibition or irritability?
- 3.Is my loved one currently on any medications—like cholinesterase inhibitors—that might actually be worsening their FTD symptoms?
- 4.Can you refer us to an occupational therapist who is familiar with the Tailored Activity Program (TAP)?
- 5.What are the specific risks for my loved one if we use atypical antipsychotics, and how will we monitor for side effects like movement disorders or heart issues?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
Boxer AL, Gold M, Feldman H, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(1)):131-143 doi:10.1016/j.jalz.2019.06.4956.
PMID: 31668596 - 2
Biological basis and psychiatric symptoms in frontotemporal dementia.
Mori K, Ikeda M
Psychiatry and clinical neurosciences 2022; (76(8)):351-360 doi:10.1111/pcn.13375.
PMID: 35557018 - 3
New Approaches to the Treatment of Frontotemporal Dementia.
Neylan KD, Miller BL
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023; (20(4)):1055-1065 doi:10.1007/s13311-023-01380-6.
PMID: 37157041 - 4
The contribution of behavioral features to caregiver burden in FTLD spectrum disorders.
Silverman HE, Ake JM, Manoochehri M, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(9)):1635-1649 doi:10.1002/alz.12494.
PMID: 34854532 - 5
Behavioral and Cognitive Response to Selective Serotonin Reuptake Inhibitors in Frontotemporal Lobar Degeneration: A Systematic Review and Meta-analysis.
Nisar M, Abubaker ZJ, Nizam MA, et al.
Clinical neuropharmacology 2021; (44(5)):175-183 doi:10.1097/WNF.0000000000000469.
PMID: 34542955 - 6
Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.
Buoli M, Serati M, Caldiroli A, et al.
Journal of geriatric psychiatry and neurology 2017; (30(3)):162-169 doi:10.1177/0891988717700506.
PMID: 28351199 - 7
Advances in Treatment of Frontotemporal Dementia.
Magrath Guimet N, Zapata-Restrepo LM, Miller BL
The Journal of neuropsychiatry and clinical neurosciences 2022; (34(4)):316-327 doi:10.1176/appi.neuropsych.21060166.
PMID: 35578801 - 8
Second-generation antipsychotics - Cardiac ion channel modulation and QT interval disturbances: A review.
Erkan O, Dai AS, Ozturk N, Ozdemir S
Biomolecules & biomedicine 2025; (26(6)):895-911 doi:10.17305/bb.2025.13405.
PMID: 41376506 - 9
Treatment of Alzheimer Disease.
Geldmacher DS
Continuum (Minneapolis, Minn.) 2024; (30(6)):1823-1844 doi:10.1212/CON.0000000000001503.
PMID: 39620846 - 10
Pharmacological Management of Dementia with Lewy Bodies.
Hershey LA, Coleman-Jackson R
Drugs & aging 2019; (36(4)):309-319 doi:10.1007/s40266-018-00636-7.
PMID: 30680679 - 11
The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study.
O'Connor CM, Clemson L, Brodaty H, et al.
Disability and rehabilitation 2019; (41(3)):299-310 doi:10.1080/09638288.2017.1387614.
PMID: 29034719 - 12
Enhancing caregivers' understanding of dementia and tailoring activities in frontotemporal dementia: two case studies.
O'Connor CM, Clemson L, Brodaty H, et al.
Disability and rehabilitation 2016; (38(7)):704-14 doi:10.3109/09638288.2015.1055375.
PMID: 26056858 - 13
Language and psychiatric symptom overlap in FTD: an SLP perspective.
Masson-Trottier M
International review of psychiatry (Abingdon, England) 2025; (37(8)):781-794 doi:10.1080/09540261.2025.2583258.
PMID: 41208381 - 14
Psychological and social impacts of frontotemporal dementia on caregivers and family members - A systematic review.
Tan YL, Lo YKJ, Ho CSH
General hospital psychiatry 2024; (86()):33-49 doi:10.1016/j.genhosppsych.2023.11.011.
PMID: 38064912 - 15
Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease.
Liu S, Liu J, Wang XD, et al.
International psychogeriatrics 2018; (30(8)):1131-1138 doi:10.1017/S1041610217002630.
PMID: 29223171 - 16
A Review of Dementia Caregiver Interventions: Valuing Psychological Well-Being and Economic Impact Through the State-Preference Method.
Consiglio A, Lopez A, Bosco A
International journal of environmental research and public health 2026; (23(1)) doi:10.3390/ijerph23010104.
PMID: 41595898
This page provides educational information on managing frontotemporal dementia (FTD) and caregiving strategies. It is not medical or legal advice; always consult your neurologist before starting or stopping medications, and seek professional counsel for legal planning.
Get notified when new evidence is published on Frontotemporal dementia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.